Datamonitor's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.
Datamonitors' Paratek Pharmaceuticals, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Paratek Pharmaceuticals, Inc. since January 2007.
– Provides intelligence on Paratek Pharmaceuticals, Inc.'s M&A, strategic partnerships and alliances, capital raising and private equity transactions. – Detailed reports of various financial transactions undertaken by Paratek Pharmaceuticals, Inc. and its subsidiaries since 2007. – Information about key financial and legal advisors for Paratek Pharmaceuticals, Inc.'s financial deals transactions. – Financial deals tables and charts covering deal value and volumes trend, deal types and geography-based deal activity.
This report includes Paratek Pharmaceuticals, Inc.'s contact information and business summary, tables, graphs, a list of partners and targets, a breakdown of financial and legal advisors, deal types, top deals by deal value, detailed deal reports, and descriptions and contact details of the partner, target, investor, and vendor firms, where disclosed.
The profile also includes detailed deal reports for all M&A, private equity, public offering, venture financing, partnership and divestment transactions undertaken by Paratek Pharmaceuticals, Inc.. These deal reports contain information about target company financials, sources of financing, method of payment, deal values, and advisors for various parties, where disclosed.
Reasons to Purchase:
– Access comprehensive financial deals data along with charts and graph covering M&A, private equity, and partnerships and alliances. – Form an independent opinion about Paratek Pharmaceuticals, Inc.’s growth strategies through the organic and inorganic activities undertaken since 2007. – Track your competitors’ business structure and growth strategies.
Our reports have been used by over 10K customers, including:
Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Human Papillomavirus (HPV) Associated Cancer - Pipeline Review, H2 2020, provides an overview of the Human Papillomavirus (HPV) Associated Cancer (Oncology)...
Fragile X Syndrome - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Fragile X Syndrome - Pipeline Review, H2 2020, provides an overview of the Fragile X Syndrome (Genetic Disorders) pipeline landscape. Fragile X syndrome is a genetic condition...
Global Gastrointestinal Partnering 2014 to 2020 provides the full collection of Gastrointestinal disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Gastrointestinal partnering deals Financial deal terms for headline, upfront and royalty by stage of development Gastrointestinal...
The Global Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2020 report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies. This report provides...
The global regenerative medicine market is projected to reach USD 17.9 billion by 2025 from USD 8.5 billion in 2020, at a CAGR of 15.9% during the forecast period. Market growth is driven by the rising prevalence of chronic diseases, genetic disorders, and cancer; rising investments in regenerative medicine research; and the growing pipeline...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.